- Drug discovery services
- Our technology
- Your benefits
- Resources & Webinars
- News & Events
- About us
Jun 29 2023
Earlier this year, the FDA made a major decision to reduce animal testing and promote alternative models for preclinical testing
Alternative models are now in a fair competition for preclinical testing and validation of new drug candidates, for oncology and other pathologies, and are actively promoted by the FDA to Replace, Reduce and Refine (3Rs) animal testing.
By removing the obligation for animal testing, this clears the way forward for alternative models to take the lead. It opens the way for economic and scientific incentives to bringing these models to maturity and acceptance within the wider Biotech and Pharma industries.
Many of these robust models, such INOVOTION’s CAM model, provide the same results as the mouse, faster and at a lower cost, with higher reliability.